Acquired by Forest Laboratories
Antibiotics for serious, life-threatening infections.
Alameda, CA
Antibiotics for serious, life-threatening infections.
Alameda, CA
Investors 1
| Date | Name | Website |
| - | New Leaf V... | nlvpartner... |
Mentions in press and media 5
| Date | Title | Description |
| 19.04.2011 | Forest Labs to buy anti-arrhythmia drug from Blue Ash Therapeutics | Cincinnati-based Blue Ash Therapeutics has reached an agreement in which Forest Laboratories (NYSE:FRX) will purchase the rights to an anti-arrhythmia drug the Ohio firm has been developing. New York-based Forest didn’t release financial te... |
| 08.09.2009 | Nycomed and Forest Laboratories to Collaborate on US Commercialisation of Daxas® in COPD | Forest Laboratories acquires exclusive commercialisation rights to Daxas® in the United States in treatment of symptomatic COPD Nycomed to receive US$100 million upfront payment plus significant milestones and royalties Daxas filed for appr... |
| 24.10.2008 | Phenomix cancels IPO, finds new lab partner | Biopharmaceuticals company Phenomix withdrew its filing to go public yesterday and right away announced a $340-million collaboration deal with Forest Laboratories. The IPO, intended to raise $86.3 million, had been pending since January. Fo... |
| 15.12.2006 | Forest Labs aquires pharma company, Cerexa, for up to $580M | Forest Laboratories said it has acquired Cerexa, a venture-backed biopharmaceutical company in Alameda, Calif., for $480 million. It will pay $100 million more if certain milestones are met. That’s a quick buy for Cerexa, which was spun out... |
| - | Forest Labs to buy anti-arrhythmia drug from Blue Ash Therapeutics | Cincinnati-based Blue Ash Therapeutics has reached an agreement in which Forest Laboratories (NYSE:FRX) will purchase the rights to an anti-arrhythmia drug the Ohio firm has been developing. New York-based Forest didn’t release financial te... |